Scientific Program Committee

CROI 2008 Session 43
c Wednesday, 2-3 pm; Room 302-304
CME
Session 42–Poster Discussion
(see Session 107 on Tuesday for corresponding Poster Abstracts)
Maternal ART and Feeding Practices: Impact on
Infant Outcomes
Discussants:
Elaine Abrams, Columbia Univ, Mailman Sch of Publ Hlth, New York, NY, US
Francois Dabis, Univ Victor Segalen, Bordeaux, France
636 18-Month HIV-free Survival by Infant Feeding Practices
in Children of HIV-infected Women in South Africa: The
Vertical Transmission Study
Nigel Rollins* 1 , R Becquet 2,3,4 , R Bland 2,5 , A Coutsoudis 1 , H Coovadia 6 , and
ML Newell 2,7
1 Univ of KwaZulu Natal, Durban, South Africa; 2 Africa Ctr for Hlth and
Population Studies, Univ of KwaZulu Natal, Somkhele, South Africa;
3 INSERM U593, Bordeaux, France; 4 Inst for Publ Hlth, Epi and Devt,
Univ Victor Segalen, Bordeaux, France; 5 Univ of Glasgow, UK; 6 Ctr for
HIV/AIDS Networking, Univ of KwaZulu Natal, Durban, South Africa;
and 7 Ctr for Pediatric Epi and Biostatistics, Inst of Child Hlth, Univ Coll
London, UK
637 Risk Factors for Mother-to-Child Transmission of HIV-1
from Breastfeeding in a Randomized Clinical Trial in
Botswana: The Mashi Study
Roger Shapiro* 1 , L Smeaton 2 , S Lockman 3 , I Thior 4 , R Rossenkhan 4 ,
C Wester 4 , L Stevens 4 , J Leidner 2 , J Makhema 4 , and M Essex 5
1 Beth Israel Deaconess Med Ctr, Boston, MA, US; 2 Harvard Sch of Publ
Hlth, Ctr for Biostatistics in AIDS Res, Boston, MA, US; 3 Brigham and
Women’s Hosp, Boston, MA, US; 4 Botswana Harvard Sch of Publ Hlth
AIDS Initiative Partnership for HIV Res and Ed, Gaborone; and 5 Harvard
Sch of Publ Hlth, Boston, MA, US
638 HIV-free Survival at 12 Months among Children Born to
HIV-infected Women Receiving Antiretrovirals from 34 to
36 Weeks of Pregnancy
Isabelle de Vincenzi* and the Kesho Bora Study Group
WHO, Geneva, Switzerland
639 Decrease in HIV-1 Mother-to-Child Transmission in Women
Receiving Postnatal HAART: 12-Month Follow-up Data
M Marazzi 1 , L Palombi 2 , G Liotta 2 , P Germano 3 , N Abdul Majid 4 , I Zimba 4 ,
A Doro Altan 2 , G Bortolot 3 , and Karin Nielsen-Saines* 5
1 LUMSA Univ, Rome, Italy; 2 Univ of Tor Vergata, Rome, Italy; 3 DREAM
Prgm, Community of St Egidio, Italy; 4 Benfica Hlth Ctr, Maputo,
Mozambique; and 5 David Geffen Sch of Med, Univ of California, Los
Angeles, US
640 Comparison of Adverse Fetal Outcomes in HIV-1-infected
Antiretroviral- naïve Pregnant Women Who Have
Received Combivir and Either Nevirapine or Nelfinavir for
Prevention of Mother-to-Child Transmission Antenatally
Rose Masaba* 1 , R Ndivo 1 , I Nyangau 1 , K Achola 1 , C Zeh 2 , M Thigpen 3 ,
P Weidle 3 , and T Thomas 2
1 Kenya Med Res Inst, Kisumu; 2 CDC Kenya, Kisumu; and 3 CDC, Atlanta,
GA, US
641 Low Birth Weight with Nevirapine-based ART in Abidjan,
Côte d’Ivoire: The ANRS Ditrame Plus Cohort and MTCT-
Plus Initiative, 2001 to 2007
Didier Koumavi Ekouevi* 1,2 , B Tonwe-Gold 1,3 , R Becquet 1 , P Coffie 1,2 ,
P Toure 3 , V Leroy 1 , I Viho 2 , S Blanche 4 , F Dabis 1 , and E Abrams 5
1 INSERM U593, Inst for Publ Hlth, Epi and Devt, Bordeaux, France;
2 Natl Agency for AIDS Res Ditrame Plus Project, Abidjan, Côte d’Ivoire;
3 ACONDA, NGO, Abidjan, Côte d’Ivoire; 4 Hosp Necker, Paris France;
and 5 MTCT-Plus Initiative, New York, NY, US
e Wednesday, 4-6 pm; Ballroom A
Session 43–Symposium CME
Accessory Proteins and Intrinsic Resistance
Conveners:
Ned Landau, New York Univ, NY, US
Aine McKnight, Barts and The London Sch
of Med and Dentistry, UK
147
Vif and APOBEC: What We Know
Xiao-Fang Yu
Johns Hopkins Univ, Baltimore, MD, US
148
The Role of Vpu in Retrovirus Particle Release
Paul Spearman
Emory Univ Sch of Med, Atlanta, GA, US
149
Genetic Variation in TRIM5α and Related Genes
Sara Sawyer* 1 , M Emerman 2 , and H Malik 2
1 Univ of Texas, Austin, US and 2 Fred Hutchinson Cancer Res Ctr,
Seattle, WA, US
150
HIV Vpr Protein as a Mediator of Ubiquitylation
Carlos de Noronha*, X Wen, L Casey, J Sharifi, and K Duus
Albany Med Coll, NY, US
Objectives: This session is directed to clinicians and scientists interested in
HIV molecular biology, viral accessory genes, mechanisms of intracellular
resistance to viruses and co-evolution of viruses and hosts. It is assumed that
participants are familiar with basic cell and molecular biology, and the HIV
genome and replication cycle. At the completion of the session participants
will be knowledgeable about the HIV Vif, Vpr, and Vpu accessory proteins
and about the APOBEC3 and Trim-5a host restriction factors.
Program 23
Wednesday
February 6 Sessions